Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose

Obesity Clinical Trial

— PRADO  

Official title:

A Pan-European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Impaired Fasting Blood Glucose With or Without Other Comorbidities

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00405808
• Other study ID #: RIMON_R_00961
• Secondary ID: EUDRACT # : 2006
• Status: Terminated
• Phase: Phase 3
• First received: November 28, 2006
• Last updated: January 25, 2011
• Start date: December 2006
• Est. completion date: February 2009

Study information

• Verified date: January 2011
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Portugal: National Pharmacy and Medicines Institute
• Study type: Interventional

Clinical Trial Summary

Primary objective:

To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with impaired fasting blood glucose and with or without associated comorbidities.

Main Secondary objectives:

To determine the effect of 12 months Rimonabant treatment versus placebo on changes in waist circumference (WC), body weight, glycemic parameters and lipid parameters.

To assess the safety of 12 months Rimonabant treatment versus placebo in these patients.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2666
• Est. completion date: February 2009
• Est. primary completion date: February 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• BMI = 30Kg/m², or > 27kg/m² if associated with risk factor(s) such as dyslipidemia, and < 40kg/m²,

• Waist Circumference > 88 cm in women; > 102 cm in men,

• Confirmed (by at least 2 measurements) impaired Fasting Plasma Glucose (FPG = 100 mg/dl (5.6 mmol/L) and < 126 mg/dl (7.0 mmol/L) in non diabetic patients,

• LDL cholesterol up to 155 mg/dl (4.00 mmol/L) including patients on a stable dose of statin therapy for at least 8 weeks prior to screening,

• Current treatment with statins and/or ezetimibe and/or antihypertensive therapy must be at fixed and stable dose for at least 8 weeks prior to screening visit,

• Patients, who are willing and in the opinion of the Investigator safely assumed to remain on stable and fixed doses of antihypertensive, and/or statins and/or ezetimibe without adding additional medications or changing current treatment for the duration of the trial.

Exclusion Criteria:

• Pregnant or breast-feeding women, or women planning to become pregnant or breastfeed (excluded by pregnancy test),

• Absence of medically approved contraceptive methods for female of childbearing potential,

• History of very low-calorie diet within 3 months prior to screening visit (lower than 1200 Kcal/day),

• Weight change > 5 kg within 3 months prior to screening visit,

• History of surgical procedures for weight loss (e.g., stomach stapling, bypass),

• History of bulimia or anorexia nervosa as per DSM-IV criteria,

• Presence of any clinically significant endocrine disease according to the investigator, in particular known abnormal TSH and free T4 blood level (Patients treated with thyroid replacement therapy must be on fixed and stable dose for at least 3 months prior to screening and must be in euthyroïd status),

• Established type 1 or 2 diabetes treated, or with at least 2 measures of fasting blood glucose = 126 mg/dl /L,

• Triglyceride level > 400 mg/dL (4.52 mmol),

• Systolic blood pressure > 160 mm Hg or diastolic blood pressure >100 mmHg at screening visit,

• Known severe renal dysfunction (creatinine clearance < 30 ml/min) or nephrotic syndrome or urinalysis (performed at screening by dipstick) showing 2+ or more protein,

• Known severe hepatic impairment or AST and/or ALT > 3 times the upper limit of normal at screening,

• Presence of any condition (medical, including clinically significant abnormal laboratory tests, psychological, social or geographical) actual or anticipated that the investigator feels would compromise the patient's safety or limit his/her successful participation to the study. In particular :

• Cardiac abnormalities: cardiac failure status NYHA III or IV, relevant acute abnormal finding seen on ECG at screening or within 6 months before screening,

• Any current malignancy or any cancer within the past five years (except adequately treated basal cell skin cancer or cervix carcinoma in situ),

• Significant haematology abnormalities (haemoglobin < 100 g/L and/or neutrophils < 1.5 G/L and/or platelets < 100 G/L),

• Acute psychiatric disorders or mental condition which could interfere with the patient's compliance or safe participation in the study,

• Patient treated for epilepsy,

• Ongoing major depressive illness,

• Uncontrolled psychiatric illness,

• History of alcohol or other substance abuse,

• Hypersensitivity /intolerance to the active substance or to any of the excipients such as lactose,

• Administration of any investigational treatment (drug or device) within 30 days prior to screening,

• Previous participation in a Rimonabant study or previous administration of Rimonabant,

• Administration of any of the following within 3 months prior to screening visit:

1. Anti obesity drugs (eg, sibutramine, orlistat),

2. Other drugs for weight reduction (phentermine, amphetamines),

3. Herbal preparations for weight reduction,

4. Nicotinic acid, fibrates or bile acid sequestrants ,

5. Prolonged use (more than one week) of systemic corticosteroids, neuroleptics.

6. Omega-3 fatty acid approved medication

• Ongoing antidepressive treatment(including bupropion)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Obesity

Intervention

Drug:
• Rimonabant
Once daily in the morning
• Placebo
Once daily in the morning

Locations

Country	Name	City	State
Austria	Sanofi-Aventis Administrative Office	Vienna
Belgium	Sanofi-Aventis Administrative Office	Diegem
Brazil	Sanofi-Aventis Administrative Office	Sao Paulo
Bulgaria	Sanofi-Aventis Administrative Office	Sofia
Canada	Sanofi-Aventis Administrative Office	Laval
Czech Republic	Sanofi-Aventis Administrative Office	Praha
Denmark	Sanofi-Aventis Administrative Office	Horsholm
Egypt	Sanofi-Aventis Administrative Office	Cairo
Finland	Sanofi-Aventis Administrative Office	Helsinki
France	Sanofi-Aventis Administrative Office	Paris
Greece	Sanofi-Aventis Administrative Office	Kallithea
Hungary	Sanofi-Aventis Administrative Office	Budapest
Ireland	Sanofi-Aventis Administrative Office	Dublin
Israel	Sanofi-Aventis Administrative Office	Natanya
Italy	Sanofi-Aventis Administrative Office	Milan
Lithuania	Sanofi-Aventis Administrative Office	Vilnius
Luxembourg	Sanofi-Aventis Administrative Office	Luxembourg
Mexico	Sanofi-Aventis Administrative Office	Col. Coyoacan
Netherlands	Sanofi-Aventis Administrative Office	Gouda
Norway	Sanofi-Aventis Administrative Office	Lysaker
Portugal	Sanofi-Aventis Administrative Office	Porto Salvo
Slovakia	Sanofi-Aventis Administrative Office	Bratislava
Spain	Sanofi-Aventis Administrative Office	Barcelona
Sweden	Sanofi-Aventis Administrative Office	Bromma
Switzerland	Sanofi-Aventis Administrative Office	Geneva
Turkey	Sanofi-Aventis Administrative Office	Istanbul
United Kingdom	Sanofi-Aventis Administrative Office	Guildford Surrey

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

Austria,  Belgium,  Brazil,  Bulgaria,  Canada,  Czech Republic,  Denmark,  Egypt,  Finland,  France,  Greece,  Hungary,  Ireland,  Israel,  Italy,  Lithuania,  Luxembourg,  Mexico,  Netherlands,  Norway,  Portugal,  Slovakia,  Spain,  Sweden,  Switzerland,  Turkey,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change in the co-primary endpoint : FPG, HDL-C and triglyceride levels.		From baseline to end of treatment	No
Secondary	Waist circumference and body weight		At each visit	No
Secondary	Glycemic parameters (FPG, fasting insulinemia, HbA1c), lipid parameters (Total Cholesterol, HDL-C, LDL-C, triglyceride levels), inflammatory parameter (Hs-CRP),		All these laboratory parameters will be measured prior to baseline, month 3, month 6 and month 12.	No
Secondary	Quality of life (IWQOL questionnaire completion)		At baseline, month 3, month 6, month 9 and month 12	No
Secondary	Incidence of adverse events in each group, including neuro-psychiatric adverse events		From the signature of the ICF to the end of the study	Yes
Secondary	Standard laboratory assessments		Prior to baseline and month 12	No